ArticleThe Journal of biological chemistry2026
IFIT3-DVL interaction promotes malignant progression of lung squamous cell carcinoma and large-cell lung carcinoma via canonical WNT signaling.
Article in The Journal of biological chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interferon-induced protein with tetratricopeptide repeat 3 (IFIT3) is involved in malignant progression. However, little information is available regarding its expression and detailed mechanisms in lung cancer. Herein, the clinicopathological significance of IFIT3 expression in lung squamous cell carcinoma (LUSC) and large-cell lung carcinoma (LCLC) specimens was assessed. IFIT3-overexpression and IFIT3-knockout LUSC/LCLC cells were generated both in vitro and in vivo. IFIT3 overexpression is correlated with advanced tumor-node-metastasis stage, lymph node metastasis, and poor prognosis in patients with LUSC and LCLC. IFIT3 promotes the malignant phenotypes of LUSC/LCLC cells in vitro and in vivo. The interaction between IFIT3 and dishevelled (DVL) in the cytoplasm of LUSC/LCLC cells was identified. Among DVL isoforms (DVL1, DVL2, DVL3), IFIT3-DVL2 interaction most prominently activates canonical wingless-type MMTV integration site family (WNT) signaling. This interaction promotes the phosphorylation of DVL2 at threonine 224 to increase the phosphorylation levels of glycogen synthase kinase-3β at serine nine and β-catenin at serine 675 and the expression of active β-catenin. Consequently, β-catenin nuclear translocation is elevated to activate β-catenin/TCF mediated transcription and upregulate the expressions of target genes of canonical WNT pathway (Cyclin D1, c-MYC, AXIN2) and the protein factors related to cell malignancy (CDK4/6, CDC42, MMP2/7/9). DVL2 knockdown or XAV-939 significantly abrogates above effects mediated by IFIT3 (p < 0.05). Overall, we demonstrated a novel signal transduction pathway where IFIT3 interacts with DVL2 to stabilize cytosolic β-catenin and promote β-catenin nuclear translocation via DVL2 phosphorylation, enhancing canonical WNT signaling activity and providing a potential target for clinical intervention in LUSC and LCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.